Ph 2 Prostate Cancer Results Strong Safety and 40% Response
Filed with ASX · · 5 pages · English
In the deck
Story so far
Earlier from Invion
- Invion secures funding through an institutional placement
- Agreement with Major South Korean Pharma Group Hanlim
- INV043 With ICI Therapy Achieved 80% Tumour Control For ASCC
- Agreement with Dr.inB to develop Photosoft treatment for HPV
- AGM Presentation
Later from Invion
- Invion Limited (ASX: IVX) Prostate Cancer Trial Results
- Consolidation/Split - IVX
- Invion Doses First Patient in Phase I/II Skin Cancer Trial
- Activities Report and Appendix 4C
- Oesophageal Cancer Collaboration and Funding Agreement
Follow Invion into a list and get an email when it puts out news.
Follow Invion